Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Surrozen Inc. Warrant (SRZNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/08/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.73% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/08/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 9036 | Beta 0.69 | 52 Weeks Range 0.01 - 0.09 | Updated Date 04/15/2025 |
52 Weeks Range 0.01 - 0.09 | Updated Date 04/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1311.76% |
Management Effectiveness
Return on Assets (TTM) -33.77% | Return on Equity (TTM) -767.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 2189393 |
Shares Outstanding - | Shares Floating 2189393 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Surrozen Inc. Warrant
Company Overview
History and Background
Surrozen, Inc. was a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on specific Wnt signaling pathways. The warrants were related to the SPAC merger that brought Surrozen public. The company ceased operations and liquidated its assets.
Core Business Areas
- Regenerative Medicine Development: Focused on developing therapies for tissue repair and regeneration using Wnt signaling pathway modulation.
Leadership and Structure
Information not available due to liquidation.
Top Products and Market Share
Key Offerings
- SZN-1326: A preclinical candidate for severe alcoholic hepatitis. No market share data available due to preclinical status. Competitors included companies developing therapies for liver diseases.
- SZN-043: A preclinical candidate for inflammatory bowel disease (IBD). No market share data available due to preclinical status. Competitors included companies developing IBD therapies.
Market Dynamics
Industry Overview
The regenerative medicine industry is focused on developing therapies to repair or replace damaged tissues and organs. This is a high-growth area with significant unmet medical needs.
Positioning
Surrozen was positioned as a developer of Wnt-signaling based regenerative medicines. Due to liquidation, their competitive position is now defunct.
Total Addressable Market (TAM)
TAM information varies depending on the specific indication (e.g., IBD, liver disease). The overall regenerative medicine market is projected to be substantial. Surrozen's liquidation means they no longer have a position in this TAM.
Upturn SWOT Analysis
Strengths
Weaknesses
- Preclinical pipeline
- High cash burn
- Dependence on Wnt signaling approach
- Ultimately failed to reach clinical milestones and secure sufficient funding
Opportunities
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
Due to liquidation, Surrozen no longer participates in the competitive landscape.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth was focused on preclinical development.
Future Projections: No future projections are relevant due to liquidation.
Recent Initiatives: Prior to liquidation, initiatives focused on advancing preclinical programs.
Summary
Surrozen Inc. ultimately failed and liquidated its assets. The company was developing regenerative medicines based on Wnt signaling but never achieved significant clinical milestones. High cash burn and preclinical development risks contributed to the company's failure. The warrants are now worthless given the company's liquidation and failure to achieve commercial success.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Third-party news sources (prior to liquidation)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The value of Surrozen Inc. warrants is likely zero due to the company's liquidation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc. Warrant
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-08-12 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, for treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.